Table 7.
Univariate analysis of factors associated with chronic neural disorder
| Item | Patients with chronic neural disorder (n=27) | Patients with effective treatment (n=43) | t/χ2 value | P value |
|---|---|---|---|---|
| Age | 0.161 | 0.688 | ||
| ≤65 years old | 17 | 25 | ||
| >65 years old | 10 | 18 | ||
| Gender | 1.004 | 0.316 | ||
| Male | 15 | 29 | ||
| Female | 12 | 14 | ||
| Treatment plan | 9.023 | 0.002 | ||
| Single treatment | 20 | 16 | ||
| Combined treatment | 7 | 27 | ||
| Chemotherapy plan | 0.774 | 0.663 | ||
| DA | 9 | 21 | ||
| R-CHOP | 10 | 10 | ||
| VAD | 8 | 12 | ||
| Disease type | 0.699 | 0.532 | ||
| Leukemia | 10 | 15 | ||
| Lymphoma | 8 | 17 | ||
| Myeloma | 9 | 11 | ||
| MNCN | 62.5±13.5 | 36.8±12.4 | 22.558 | <0.001 |
| SNCV | 59.1±10.3 | 41.8±11.5 | 11.772 | <0.001 |
| Chemotherapy course | 7.4±2.5 | 5.8±3.0 | 8.440 | 0.034 |
Note: DA: Daunorubicin + Cytarabine; R-CHOP: Rituxima + Cyclophosphamide + Doxorubicin + Vincristine + Prednisone; VAD: Vincristine + Doxorubicin + Dexamethasone; MNCV: motor nerve conduction velocity; SNCV: sensory nerve conduction velocity.